Cargando…
Blood pressure: at what level is treatment worthwhile?
High blood pressure is a key modifiable risk factor for cardiovascular events. A cardiovascular risk-based approach is best for determining when to start antihypertensive treatment Recent trial evidence has suggested lower blood pressure targets are beneficial. This has influenced international guid...
Autores principales: | , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
NPS MedicineWise
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6698244/ https://www.ncbi.nlm.nih.gov/pubmed/31427843 http://dx.doi.org/10.18773/austprescr.2019.038 |
_version_ | 1783444514942222336 |
---|---|
author | Atkins, Emily R Perkovic, Vlado |
author_facet | Atkins, Emily R Perkovic, Vlado |
author_sort | Atkins, Emily R |
collection | PubMed |
description | High blood pressure is a key modifiable risk factor for cardiovascular events. A cardiovascular risk-based approach is best for determining when to start antihypertensive treatment Recent trial evidence has suggested lower blood pressure targets are beneficial. This has influenced international guidelines. The US guidelines have a lower threshold for defining hypertension than current Australian and European guidelines The patient’s individual circumstances must be considered when treatment targets are set. For someone with a high risk of cardiovascular events, a systolic blood pressure target of 120 mmHg may be appropriate |
format | Online Article Text |
id | pubmed-6698244 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | NPS MedicineWise |
record_format | MEDLINE/PubMed |
spelling | pubmed-66982442019-08-19 Blood pressure: at what level is treatment worthwhile? Atkins, Emily R Perkovic, Vlado Aust Prescr Article High blood pressure is a key modifiable risk factor for cardiovascular events. A cardiovascular risk-based approach is best for determining when to start antihypertensive treatment Recent trial evidence has suggested lower blood pressure targets are beneficial. This has influenced international guidelines. The US guidelines have a lower threshold for defining hypertension than current Australian and European guidelines The patient’s individual circumstances must be considered when treatment targets are set. For someone with a high risk of cardiovascular events, a systolic blood pressure target of 120 mmHg may be appropriate NPS MedicineWise 2019-08-01 2019-08 /pmc/articles/PMC6698244/ /pubmed/31427843 http://dx.doi.org/10.18773/austprescr.2019.038 Text en (c) NPS MedicineWise 2019 https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution Non-Commercial No Derivatives (CC BY-NC-ND) 4.0 License. |
spellingShingle | Article Atkins, Emily R Perkovic, Vlado Blood pressure: at what level is treatment worthwhile? |
title | Blood pressure: at what level is treatment worthwhile? |
title_full | Blood pressure: at what level is treatment worthwhile? |
title_fullStr | Blood pressure: at what level is treatment worthwhile? |
title_full_unstemmed | Blood pressure: at what level is treatment worthwhile? |
title_short | Blood pressure: at what level is treatment worthwhile? |
title_sort | blood pressure: at what level is treatment worthwhile? |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6698244/ https://www.ncbi.nlm.nih.gov/pubmed/31427843 http://dx.doi.org/10.18773/austprescr.2019.038 |
work_keys_str_mv | AT atkinsemilyr bloodpressureatwhatlevelistreatmentworthwhile AT perkovicvlado bloodpressureatwhatlevelistreatmentworthwhile |